Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

October 3, 2018 by Alan Khadavi

Tralokinumab for Asthma

Tralokinumab is an IL-13 neutralizing monoclonal antibody being investigated for severe asthma.  The success of neutralization of IL-5 for the treatment of severe eosinophilic asthma has increased investigation into the therapeutic potential  of other type 2 cytokines, including IL-13.

3 recent trials have been conducted to assess the efficacy of tralokinumab, an IL-13 neutralizing mAb, in the treatment of asthma.  A study published in the Lancet, studied patients with moderate to severe asthma, they either received placebo or 300mg of tralokinumab every 2 weeks for 12 weeks.

Tralokinumab decreased the fraction of nitric oxide and total blood IgE levels, it did not affect eosinophil counts in the blood and sputum.

In other study, tralokinumab was given every 2 or 4 weeks vs placebo.  Tralokinumab did not significantly reduced the overall annualized asthma exacerbation rate.

These findings support the idea that neutralization of IL-13 alone is not sufficient to prevent asthma exacerbation and suggest a requirement for concurrent neutralization of IL-4, by Dupilumab.

Dupilumab for Asthma, a New Indication

There are many new biologic medications that are being studied, to read more about them, see here:

Allergy Biologics, Past, Present and Future…

Currently on the market, the biologics that are FDA approved and available are, Xolair, Nucala, Fasenra and Cinqair.

New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma

Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil)

Fasenra (Benralizumab) for Severe Asthma

In addition to asthma, other indications are being looked at.  For instance, Xolair was initially approved for asthma, but it is now indicated chronic hives.

FDA approves Xolair for Chronic Urticaria

Other conditions being looked at are COPD, nasal polyps, eosinophilic esophagitis, to name a few.

Overall, the studies for tralokinumab are not promising for severe asthma, more studies will be coming.  But if they are not able to get approval, other indications may be on the horizon for it.

 

Filed Under: Asthma, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page